NEO New Oncology
NEO New Oncology AG's "NEO" diagnostic platform allows doctors to determine the optimal targeted therapy for their patients. This also includes the possibility to participate in appropriate clinical trials. NEO identifies all therapy-relevant genetic alterations from standard clinical material quickly, reliably and irrespective of indications. With NEO, point mutations, as well as amplifications, small insertions or deletions and selected known and new translocations can be detected from a single patient sample. NEO New Oncology AG works together with renowned cancer experts to make the latest scientific findings available for improvements in patient care.
About NEO New Oncology
Founded
2012Estimated Revenue
$1M-$10MEmployees
11-50Funding / Mkt. Cap
$6MCategory
Industry
BiotechnologyLocation
City
KoelnState
North Rhine-WestphaliaCountry
GermanyNEO New Oncology
Find your buyer within NEO New Oncology